Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma

The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay. The investigators also study the pattern of microRNA from patients with diffuse large B-cell lymphoma. The results of gene expression profiles and microRNA is correlated with clinical outcomes of diffuse large B-cell lymphoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diffuse Large B-cell Lymphoma Disease Attributes Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

15 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Cancer Research Institute

Seoul, 135-710, South Korea

About this study

Whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay

Diffuse large B-cell lymphoma patients
Paraffin-embedded tissue
End points: Progression-free survival, overall survival
Statistics: Leave one-out method
Nano string assay for microRNA

Diffuse large B-cell lymphoma patients
Paraffin-embedded tissue
End points: Progression-free survival, overall survival
Statistics: Leave one-out method

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with diffuse large B-cell lymphoma
Patients with tissue blocks available for study
Patients with adequate medical records

Exclusion criteria

Patients diagnosed with other subtypes of lymphoma

Treatment and study plan

Primary outcomes

Number of patients who relapse or progress after 1st line chemotherapy

Time frame: two years

Secondary outcomes

Number and type of genes and microRNA which are significantly related with relapse or progression (P < 0.05)

Time frame: two years

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Retrospective Analysis of Diffuse Large B-cell Lymphoma: Identification of Factors Associated With Treatment Resistance Via Gene Expression Profile

Important dates

Study start: 2011
Primary completion: 2012
Study completion: 2012
First posted: May 25, 2012
Registry last updated: Jan 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed